Acrux (ASX:ACR) — Material Events
ASX:ACR · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Acrux Unveils 449% Growth in Generics Licensing and New R&D Focus at 2025 AGMMedium
Acrux reports strong generic portfolio growth and strategic focus on new R&D at 2025 AGM
25 Nov 2025
·Annual General Meeting Presentation
·75
Acrux Secures AUD 5.4 Million Milestone Deal for Lenzetto to Address Australian Menopause Therapy ShortageMedium
Acrux secures AUD 5.4 million milestone deal for Lenzetto® to address Australian menopause therapy shortage
28 May 2026
·Licensing Agreement Amendment
·75
Acrux Navigates Market Headwinds with New US Generics and Saudi Licensing DealMedium
Acrux reports FY25 results with revenue down 44%, net loss rises 2%, launches 3 US generics, pivots to new markets
29 Aug 2025
·Annual Report and Appendix 4E
·75
Acrux Boosts US Footprint and Eyes Hormone Therapy Growth Amid Portfolio ShiftMedium
Acrux reports revenue growth, portfolio expansion, and strategic pivot to HRT with increased cash reserves
29 Jan 2026
·Quarterly Activities Report and Appendix 4C
·75
Acrux Surpasses Prior Year Profit Share in September QuarterMedium
Acrux posts strong quarterly revenue growth and repays R&D advances in September 2025 quarter
31 Oct 2025
·Quarterly Activities Report and Appendix 4C
·75
Acrux Accelerates US Growth with New Topical Generics and Fresh CEO LeadershipMedium
Acrux reports revenue growth from new US topical generics and secures RDTI funding; new CEO appointed
30 July 2025
·Quarterly Activities Report and Appendix 4C
·75
Acrux Expands Reach with 10-Year Saudi Licensing Deal for Dapsone GelMedium
Acrux inks 10-year Saudi Arabia licensing deal for FDA-approved Dapsone 5% Gel with Servacure
31 July 2025
·Licensing Agreement Announcement
·70
Acrux Secures $1.6 Million Placement to Back Female Testosterone TrialsMedium
Acrux raises $1.6 million via discounted share placement with attaching options
11 May 2026
·Capital Raising
·70
Acrux Secures AUD 5.4 Million Milestone Deal for Lenzetto in AustraliaMedium
Acrux licenses Lenzetto® for Australia with AUD 5.4 million milestone deal
29 May 2026
·Licensing Update
·70
Acrux Divests US Rights for Prilocaine/Lidocaine Cream to Boost HRT FocusMedium
Acrux divests US rights for Prilocaine/Lidocaine Cream for $550K to fund HRT development
12 Dec 2025
·ASX Release
·50
Acrux Secures $3.04M R&D Rebate, Clears Funding FacilityMedium
Acrux receives $3.04M R&D Tax Rebate and repays funding facility
4 Sept 2025
·ASX Release
·50
Acrux Shareholders Retain Capital Gains Tax Exemptions After Budget ChangesMedium
Acrux Capital Gains Tax Exemptions Unaffected by 2026/27 Federal Budget Changes
14 May 2026
·Regulatory Update
·50
Acrux Advances $0.55M R&D Tax Incentive to Boost Hormone Therapy ProgressMedium
Acrux secures $0.55M advance on FY26 R&D Tax Incentive to support HRT development
12 Mar 2026
·ASX Release
·50
No articles in this tier for the last 12 months.
Market Mentions
4
- appeared in market wrap coverage
These are market wrap articles where Acrux (ASX:ACR) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 22 (25 May -> 29 May) 2026
30 May 2026
Market Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 11 (9 Mar -> 13 Mar) 2026
14 Mar 2026